Laddar populära aktier...
The company's Q3 net sales and adjusted EBIT were close to LSEG Data & Analytics consensus.
EMS market has been weak but Incap was able to improve net sales in y/y and also in q/q basis.
Several EMS companies have claimed weak end demand in H2 2024.
Net sales and clean EBIT were in line with consensus but the share price declined by 7.
Net sales and adjusted EBIT were close to market consensus (LSEG) in Q2.
Incap upgraded its 2024 full-year guidance on 18 July.
Incap upgraded its 2024 full year guidance. Net sales is now guided to grow (previously decline) in 2024 y/y.
This year could turn out to be better than expected for Incap.
Net sales were 12% above consensus (LSEG) in Q1. Revenue decreased by 29% y/y in Q1 but grew by 38% y/y when excluding the company’s largest...
Net sales have declined for the last four quarters on a q/q basis but this trend could come to an end in Q1 2024.
Incap's Q4 net sales and adjusted EBIT margin beat consensus (LSEG Data & Analytics) expectations.
Net sales was 7% above consensus (LSEG) in Q4. Also adjusted EBIT margin of 10.
Our estimates for net sales and EBIT are slightly above consensus for Q4.
Q3 net sales and clean EBIT were above Refinitiv consensus expectations.
Net sales was above consensus (Refinitiv) in Q3. Clean operating profit margin was also better than consensus in Q3.
Incap downgraded its 2023 guidance on 5 October due to weaker-than-expected orders from its main customer, which is conducting an inventory ...
Incap is relatively confident about its full-year net sales development, despite inventory destocking by its main customer.
Net sales was close to consensus (Refinitiv) in Q2.
We expect relatively good Q2 results, but H2 2023 estimates include a lot of uncertainty due to a major customer's need to reduce inventory.
Quality, reliable delivery and low costs are the main success factors in the competitive EMS sector and, in our view, Incap has them all.